Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations. The post Numinus Closes Bioscience Lab...
Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations. The post Numinus Closes Bioscience Lab...
Fed worker marijuana bill scaled back; NH weighs “franchise” legalization model; CA bills on gov’s desk; OR drug decrim repeal; OH GOP ballot oppo...
Renowned hedge fund manager and Wall Street mogul Steve Cohen is showing his confidence in the psychedelic sector. Cohen’s hedge The post Cybin Rallies...
Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin. The post Billionaire Investor Steve Cohen Buys 19 million Shares...
The global inflation surge and monetary policy tightening by major central banks have all contributed to the market volatility this year. Despite that,...
Leading psychedelic drugs market players include Research Nester are COMPASS Pathways plc, Silo Pharma, Inc., Numinus Wellness Inc., Cybin Inc., Mind Medicine...
Preliminary DMT therapy data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024. The post Cybin Lands Key U.S....
The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs. The post Cybin Granted U.S. Patent for 5-MeO-DMT appeared...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small...